Genmab | GEN - Net Income


Genmab reported DKK303M in Net Income for its fiscal quarter ending in June of 2026.





Net Income Change Date
Agios Pharmaceuticals USD -99.11M 8.93M Mar/2026
Almirall EUR 19.58M 7M Dec/2025
Amarin USD -1.22M 6.51M Dec/2025
Amgen USD 2.38B 556M Jun/2026
argenx SE USD 472M 106M Jun/2026
AstraZeneca USD 2.51B 573M Jun/2026
Bayer EUR 219M 2.54B Jun/2026
BioMarin Pharmaceutical USD 44.76M 60.76M Jun/2026
Demant DKK 1.18B 758M Jun/2026
Exelixis USD 212.05M 1.58M Jun/2026
Fresenius Medical Care EUR 218.38M 100.38M Jun/2026
Genmab DKK 303M 250M Jun/2026
GlaxoSmithKline GBP 435M 1.3B Jun/2026
GN Store Nord DKK -22M 933M Jun/2026
GRIFOLS EUR 154M 81M Jun/2026
Hikma Pharmaceutical USD 164M 45M Dec/2025
Insmed USD -13.24M 150.32M Jun/2026
Lakefront Biotherapeutics EUR 2.11M 12.38M Jun/2026
Lonza CHF 426M 119M Jun/2025
Merck EUR 490M 169M Jun/2026
Novartis USD 3.26B 108M Jun/2026
Regeneron Pharmaceuticals USD 1.3B 569.7M Jun/2026
Roche Holding CHF 6.87B 1.4B Jun/2026
Sanofi EUR 343M 1.27B Jun/2026
UCB EUR 1.08B 608M Dec/2025